23rd Oct 2013 07:46
LONDON (Alliance News) - Deltex Medical Group PLC Wednesday said it has established a third dedicated trainer account in the US, as another hospital agreed to implement its oesophageal doppler monitoring technology, and it expects further deals in coming months.
The new US hospital is one of two that agreed to adopt the technology earlier in the year, it said.
The company appoints dedicated clinical trainers to support implementation of the technology. It said the trainer is now in place and the hospital will initially focus on the highest risk surgical patients, estimated at 60 per month, with a view to expanding it to all major and high risk surgery in future phases.
"This is the third dedicated trainer account we have established in the USA and comes after a period in which we have seen the strong expansion in the pipeline of US hospitals considering broad and deep adoption of oesophageal doppler monitoring," Deltex Chief Executive Ewan Phillips said in a statement.
"We expect to announce further expansion of the Deltex dedicated trainer programme in the coming months as more hospitals move from evaluation and early implementation towards wide-scale implementation of oesophageal doppler monitoring," he added.
No financial details were provided.
Deltex claims oesophageal doppler monitoring is the only therapy to measure blood flow in the central circulation in real time. Randomised, controlled trials using doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay, it says.
Deltex shares were up 7.3% at 16.5 pence early Wednesday, one of the biggest rises on AIM.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Deltex Medical